Profile of rolipram treated B-CLL, normal B, and normal T cells
Ontology highlight
ABSTRACT: PDE4 inhibitors, which activate cAMP signaling by reducing cAMP catabolism, are known to induce apoptosis in B lineage chronic lymphocytic leukemia (CLL) cells but not normal human T cells. The explanation for such differential sensitivity remains unknown. Here, we report studies contrasting the response to PDE4 inhibitor treatment in CLL cells and normal human T and B cells. Affymetrix gene chip analysis in the three cell populations following treatment with the PDE4 inhibitor rolipram identified a set of up-regulated transcripts with unusually high fold-changes in the CLL samples, several of which are likely part of compensatory negative feedback loops. The high fold-change were due to low basal transcript levels in CLL cells, suggesting that cAMP-mediated signaling may be unusually tightly regulated in this cell type. Keywords: drug response
ORGANISM(S): Homo sapiens
PROVIDER: GSE13987 | GEO | 2009/03/01
SECONDARY ACCESSION(S): PRJNA112481
REPOSITORIES: GEO
ACCESS DATA